Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
820 patients, 804 were included in the current evaluation, 407 patients received HF and 397 CF radiation therapy.
I · Intervention 중재 / 시술
HF and 397 CF radiation therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] In the updated findings, we could not demonstrate a statistically significant improvement in 10-year relapse-free survival following dose escalated HF compared with CF. Although patients in the HF arm showed a favorable 10-year overall survival, this difference did not remain statistically significant in the multivariable analysis.
[PURPOSE] The HYpofractionated irradiation for PROstate cancer trial was a multicenter, randomized, phase 3, superiority trial comparing dose escalated hypofractionation (HF) with conventional fractio
- 95% CI 58.6-69.7
APA
Wiersma RG, de Vries KC, et al. (2026). Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial.. International journal of radiation oncology, biology, physics, 124(4), 928-936. https://doi.org/10.1016/j.ijrobp.2025.09.067
MLA
Wiersma RG, et al.. "Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial.." International journal of radiation oncology, biology, physics, vol. 124, no. 4, 2026, pp. 928-936.
PMID
41106690 ↗
Abstract 한글 요약
[PURPOSE] The HYpofractionated irradiation for PROstate cancer trial was a multicenter, randomized, phase 3, superiority trial comparing dose escalated hypofractionation (HF) with conventional fractionation (CF) for the treatment of localized intermediate- and high-risk prostate cancer. This trial aimed to demonstrate equivalent toxicity of HF. In prior publications, noninferiority of acute and late toxicity could not be established. Here, we report the long-term survival outcomes.
[METHODS AND MATERIALS] We randomly assigned patients (1:1) with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer to receive either HF (64.4 Gy in 19 fractions of 3.4 Gy, 3 fractions per week) or CF (78.0 Gy in 39 fractions of 2 Gy, 5 fractions per week) radiation therapy. The HF schedule was a dose escalation compared with CF, based on a α/β ratio of prostate cancer of ∼1.5 Gy, the equivalent total dose in fractions of 2 Gy is 90.4 Gy for HF versus 78.0 Gy for CF. The primary endpoint of this paper was relapse-free survival at 10 years and secondary outcome was overall survival.
[RESULTS] Of the 820 patients, 804 were included in the current evaluation, 407 patients received HF and 397 CF radiation therapy. The 10-year relapse-free survival was 64.5% (95% CI, 58.6-69.7) in the HF arm compared with 60.1% (95% CI, 53.9-65.8) in the CF arm (hazard ratio, 0.89; 95% CI, 0.69-1.14; P = .35). The 10-year overall survival in the HF arm was 69.2% (95% CI, 64.1-73.7) versus 61.2% (95% CI, 55.7-66.2) in the CF arm (hazard ratio, 0.82; 95% CI, 0.65-1.05; P = .11).
[CONCLUSIONS] In the updated findings, we could not demonstrate a statistically significant improvement in 10-year relapse-free survival following dose escalated HF compared with CF. Although patients in the HF arm showed a favorable 10-year overall survival, this difference did not remain statistically significant in the multivariable analysis.
[METHODS AND MATERIALS] We randomly assigned patients (1:1) with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer to receive either HF (64.4 Gy in 19 fractions of 3.4 Gy, 3 fractions per week) or CF (78.0 Gy in 39 fractions of 2 Gy, 5 fractions per week) radiation therapy. The HF schedule was a dose escalation compared with CF, based on a α/β ratio of prostate cancer of ∼1.5 Gy, the equivalent total dose in fractions of 2 Gy is 90.4 Gy for HF versus 78.0 Gy for CF. The primary endpoint of this paper was relapse-free survival at 10 years and secondary outcome was overall survival.
[RESULTS] Of the 820 patients, 804 were included in the current evaluation, 407 patients received HF and 397 CF radiation therapy. The 10-year relapse-free survival was 64.5% (95% CI, 58.6-69.7) in the HF arm compared with 60.1% (95% CI, 53.9-65.8) in the CF arm (hazard ratio, 0.89; 95% CI, 0.69-1.14; P = .35). The 10-year overall survival in the HF arm was 69.2% (95% CI, 64.1-73.7) versus 61.2% (95% CI, 55.7-66.2) in the CF arm (hazard ratio, 0.82; 95% CI, 0.65-1.05; P = .11).
[CONCLUSIONS] In the updated findings, we could not demonstrate a statistically significant improvement in 10-year relapse-free survival following dose escalated HF compared with CF. Although patients in the HF arm showed a favorable 10-year overall survival, this difference did not remain statistically significant in the multivariable analysis.